Evidence mapPaperPMID 40871010Full record

ReviewPharmaceutics2025

Nanomedicine: The Effective Role of Nanomaterials in Healthcare from Diagnosis to Therapy.

Raisa Nazir Ahmed Kazi, Ibrahim W Hasani, Doaa S R Khafaga, Samer Kabba, Mohd Farhan, Mohammad Aatif, Ghazala Muteeb, Yosri A Fahim

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Raisa Nazir Ahmed KaziDepartment of Respiratory Therapy, College of Applied Medical Sciences, King Faisal University, Al-Ahsa 31982, Saudi Arabia.
Ibrahim W HasaniDepartment of Pharmaceutics, Faculty of Pharmacy, AL-Shamal Private University (S.P.U.), Mari Private University (M.P.U.) and Idlib University, Idlib 5100, Syria.ORCID 0000-0002-7333-5851
Doaa S R KhafagaDepartment of Basic Medical Sciences, Health Sector, Galala University, Suez 43511, Egypt.ORCID 0000-0002-0576-0100
Samer KabbaDepartment of Pharmaceutical Technology, AL-Shamal Private University (S.P.U.), Idlib 5100, Syria.ORCID 0009-0003-7482-0079
Mohd FarhanDepartment of Chemistry, College of Science, King Faisal University, Al-Ahsa 31982, Saudi Arabia.ORCID 0000-0002-1519-9644
Mohammad AatifDepartment of Public Health, College of Applied Medical Sciences, King Faisal University, Al-Ahsa 31982, Saudi Arabia.ORCID 0000-0002-1748-2160
Ghazala MuteebDepartment of Nursing, College of Applied Medical Sciences, King Faisal University, Al-Ahsa 31982, Saudi Arabia.ORCID 0000-0002-3328-3559
Yosri A FahimDepartment of Basic Medical Sciences, Health Sector, Galala University, Suez 43511, Egypt.ORCID 0000-0002-1009-7577

Funding

Deanship of Scientific Research, Vice Presidency for Graduate Studies and Scientific Research, King Faisal University, Saudi Arabia KFU251234
6 · The paper itself

Abstract

Nanotechnology is revolutionizing medicine by enabling highly precise diagnostics, targeted therapies, and personalized healthcare solutions. This review explores the multifaceted applications of nanotechnology across medical fields such as oncology and infectious disease control. Engineered nanoparticles (NPs), such as liposomes, polymeric carriers, and carbon-based nanomaterials, enhance drug solubility, protect therapeutic agents from degradation, and enable site-specific delivery, thereby reducing toxicity to healthy tissues. In diagnostics, nanosensors and contrast agents provide ultra-sensitive detection of biomarkers, supporting early diagnosis and real-time monitoring. Nanotechnology also contributes to regenerative medicine, antimicrobial therapies, wearable devices, and theranostics, which integrate treatment and diagnosis into unified systems. Advanced innovations such as nanobots and smart nanosystems further extend these capabilities, enabling responsive drug delivery and minimally invasive interventions. Despite its immense potential, nanomedicine faces challenges, including biocompatibility, environmental safety, manufacturing scalability, and regulatory oversight. Addressing these issues is essential for clinical translation and public acceptance. In summary, nanotechnology offers transformative tools that are reshaping medical diagnostics, therapeutics, and disease prevention. Through continued research and interdisciplinary collaboration, it holds the potential to significantly enhance treatment outcomes, reduce healthcare costs, and usher in a new era of precise and personalized medicine.

Indexed as

drug delivery systemhealthcarenanobotsnanomedicinenanozyme

Identifiers

PMID40871010
PMCPMC12389108

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.